Compare Amphastar Pharmaceuticals Inc (AMPH) vs Levi Strauss & Co. (LEVI) Price & Performance

AMPH trades at $18.72, down 1.58% with bearish technical signals despite oversold RSI readings. The company reported mixed Q1 2026 results with EPS of $0.42 missing estimates of $0.70, continuing a trend of recent earnings disappointments. Valuation metrics appear reasonable with P/E of 11.29 and P/B of 1.07, while profitability remains solid with 47.34% gross margins. Recent news includes a Zacks Strong Sell rating and ongoing securities law investigation.

The stock faces near-term headwinds from earnings misses and negative analyst sentiment, though current valuations provide some downside protection. Upside potential exists if the company can execute its strategic pivot to proprietary drugs and biosimilars while managing BAQSIMI discount pressures. Key risks include ongoing legal scrutiny and competitive pressures in the generic drug market.

Levi Strauss (LEVI) trades at $24.31, up 2.02% today, showing strong fundamental performance with consistent earnings beats and robust profitability metrics. The company recently raised its dividend and full-year guidance following Q2 2026 results, demonstrating confidence in its digital strategy and direct-to-consumer growth. Technical indicators show mixed signals with bearish overall momentum but strong support at $23. Analyst consensus remains overwhelmingly bullish with an 83% buy rating and $28 price target, representing 15% upside potential.

LEVI presents a compelling investment case with strong fundamentals, consistent earnings outperformance, and positive business momentum. Key opportunities include the successful digital transformation, expanding direct-to-consumer sales, and dividend growth. Risks include tariff pressures, foreign exchange volatility, and competitive retail landscape. The stock offers attractive valuation with 15% upside to consensus target, supported by strong cash flow generation and improving balance sheet metrics.